Ausgabe 2/2011
Inhalt (27 Artikel)
Announcement
Phase II study of S-1 in patients with gemcitabine-resistant advanced pancreatic cancer
Kentaro Sudo, Taketo Yamaguchi, Kazuyoshi Nakamura, Tadamichi Denda, Taro Hara, Takeshi Ishihara, Osamu Yokosuka
Pharmacokinetics in mice and metabolism in murine and human liver fractions of the putative cancer chemopreventive agents 3′,4′,5′,5,7-pentamethoxyflavone and tricin (4′,5,7-trihydroxy-3′,5′-dimethoxyflavone)
Hong Cai, Stewart Sale, Robert G. Britton, Karen Brown, William P. Steward, Andreas J. Gescher
In vitro anti-mesothelioma activity of cisplatin–gemcitabine combinations: evidence for sequence-dependent effects
Ilaria Zanellato, Carla Doriana Boidi, Guido Lingua, Pier-Giacomo Betta, Sara Orecchia, Elena Monti, Domenico Osella
Schedule treatment design and quantitative in vitro evaluation of chemotherapeutic combinations for metastatic prostate cancer therapy
Ana Catarina Pinto, Susana Ângelo, João Nuno Moreira, Sérgio Simões
Tamoxifen and raloxifene suppress the proliferation of estrogen receptor-negative cells through inhibition of glutamine uptake
Valentina K. Todorova, Yihong Kaufmann, Shaoke Luo, V. Suzanne Klimberg
A novel bis-indole destabilizes microtubules and displays potent in vitro and in vivo antitumor activity in prostate cancer
Sunjoo Ahn, Dong Jin Hwang, Christina M. Barrett, Jun Yang, Charles B. Duke III, Duane D. Miller, James T. Dalton
Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors
Anne M. Traynor, Maureen Hewitt, Glenn Liu, Keith T. Flaherty, Jason Clark, Steven J. Freedman, Boyd B. Scott, Ann Marie Leighton, Patricia A. Watson, Baiteng Zhao, Peter J. O’Dwyer, George Wilding
A phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma
Fumihiko Kanai, Haruhiko Yoshida, Ryosuke Tateishi, Shinpei Sato, Takao Kawabe, Shuntaro Obi, Yuji Kondo, Makoto Taniguchi, Kazumi Tagawa, Masafumi Ikeda, Chigusa Morizane, Takuji Okusaka, Hitoshi Arioka, Shuichiro Shiina, Masao Omata
Phase I study of the combination of nedaplatin and gemcitabine in previously untreated advanced squamous cell lung cancer
Katsuhiro Masago, Shiro Fujita, Young Hak Kim, Yukimasa Hatachi, Akiko Fukuhara, Kaoru Irisa, Hiroki Nagai, Yuichi Sakamori, Yosuke Togashi, Tadashi Mio, Michiaki Mishima
Serum levels of surfactant protein D predict the anti-tumor activity of gefitinib in patients with advanced non-small cell lung cancer
Hiroyuki Yamaguchi, Hiroshi Soda, Yoichi Nakamura, Mineyo Takasu, Nanae Tomonaga, Hirofumi Nakano, Seiji Doi, Katsumi Nakatomi, Seiji Nagashima, Hiroshi Takatani, Minoru Fukuda, Tomayoshi Hayashi, Kazuhiro Tsukamoto, Shigeru Kohno
Cetuximab and circadian chronomodulated chemotherapy as salvage treatment for metastatic colorectal cancer (mCRC): safety, efficacy and improved secondary surgical resectability
Francis Lévi, Abdoulaye Karaboué, Lee Gorden, Pasquale Fabio Innominato, Raphael Saffroy, Sylvie Giacchetti, Dominique Hauteville, Catherine Guettier, René Adam, Mohamed Bouchahda
Pharmacokinetics and pharmacodynamics of AZD6244 (ARRY-142886) in tumor-bearing nude mice
Cathrine L. Denton, Daniel L. Gustafson
Second-line chemotherapy with Capecitabine (Xeloda) and Docetaxel (Taxotere) in previously treated, unresectable adenocarcinoma of pancreas: the final results of a phase II trial
Ourania Katopodis, Aris Polyzos, Nikolaos Kentepozidis, Stylianos Giassas, Maria Rovithi, Vasiliki Bozionelou, Kostas Kalbakis, Lambros Vamvakas, Dimitris Mavroudis, Vassilis Georgoulias
Chemotherapeutic activity of silymarin combined with doxorubicin or paclitaxel in sensitive and multidrug-resistant colon cancer cells
Valentina Colombo, Monica Lupi, Francesca Falcetta, Daniele Forestieri, Maurizio D’Incalci, Paolo Ubezio
Mechanistic study of BNP7787-mediated cisplatin nephroprotection: modulation of human aminopeptidase N
F. H. Hausheer, A. R. Parker, P. N. Petluru, K. W. Jair, S. Chen, Q. Huang, X. Chen, P. Y. Ayala, D. Shanmugarajah, H. Kochat
Population pharmacokinetics of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (Triapine®) in cancer patients
Jill Kolesar, Richard C. Brundage, Marcia Pomplun, Dona Alberti, Kyle Holen, Anne Traynor, Percy Ivy, George Wilding
Combination effects of platinum drugs and N 1, N 11 diethylnorspermine on spermidine/spermine N 1-acetyltransferase, polyamines and growth inhibition in A2780 human ovarian carcinoma cells and their oxaliplatin and cisplatin-resistant variants
Ramakumar Tummala, Paula Diegelman, Suzanne Hector, Debora L. Kramer, Kimberly Clark, Patricia Zagst, Gerald Fetterly, Carl W. Porter, Lakshmi Pendyala
Risk factors contributing to the development of carboplatin-related delayed hypersensitivity reactions in Japanese patients with gynecologic cancers
Hiroko Sugimoto, Takuya Iwamoto, Yukiko Murashima, Tsutomu Tabata, Norimasa Sagawa, Masahiro Okuda
Plasma pharmacokinetics and oral bioavailability of the 3,4,5,6-tetrahydrouridine (THU) prodrug, triacetyl-THU (taTHU), in mice
Jan H. Beumer, Julie L. Eiseman, Judith A. Gilbert, Julianne L. Holleran, Archibong E. Yellow-Duke, Dana M. Clausen, David Z. D’Argenio, Matthew M. Ames, Pamela A. Hershberger, Robert A. Parise, Lihua Bai, Joseph M. Covey, Merrill J. Egorin
A phase I study of OSI-461 in combination with mitoxantrone in patients with advanced solid tumors potentially responsive to mitoxantrone
Lee P. Resta, Roberto Pili, Mario A. Eisenberger, Avery Spitz, Serina King, Jennifer Porter, Amy Franke, Ramesh Boinpally, Michael A. Carducci, Christopher J. Sweeney
Histone deacetylase inhibitor (HDACI) PCI-24781 potentiates cytotoxic effects of doxorubicin in bone sarcoma cells
Cao Yang, Edwin Choy, Francis J. Hornicek, Kirkham B. Wood, Joseph H. Schwab, Xianzhe Liu, Henry Mankin, Zhenfeng Duan
A first in human study of SB-743921, a kinesin spindle protein inhibitor, to determine pharmacokinetics, biologic effects and establish a recommended phase II dose
Kyle D. Holen, Chandra P. Belani, George Wilding, Suresh Ramalingam, Jennifer L. Volkman, Ramesh K. Ramanathan, Lakshmi S. Vasist, Carolyn J. Bowen, Jeffrey P. Hodge, Mohammed M. Dar, Peter T. C. Ho
Phase I and pharmacokinetic study of lonafarnib, SCH 66336, using a 2-week on, 2-week off schedule in patients with advanced solid tumors
Carlos Castaneda, Kellen L. Meadows, Roxanne Truax, Michael A. Morse, Scott H. Kaufmann, William P. Petros, Yali Zhu, Paul Statkevich, David L. Cutler, Herbert I. Hurwitz
A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE)
Karen E. Bullock, William P. Petros, Islam Younis, Hope E. Uronis, Michael A. Morse, Gerard C. Blobe, S. Yousuf Zafar, Jon P. Gockerman, Joanne J. Lager, Roxanne Truax, Kellen L. Meadows, Leigh A. Howard, Margot M. O’Neill, Gloria Broadwater, Herbert I. Hurwitz, Johanna C. Bendell
Clinical effect of erlotinib as first-line treatment for Asian elderly patients with advanced non-small-cell lung cancer
Xin-Hua Xu, Jin Su, Xiang-Yang Fu, Feng Xue, Qiao Huang, Dao-Jun Li, Ming-Qian Lu
The role of K-Ras gene mutation in TRAIL-induced apoptosis in pancreatic and lung cancer cell lines
Ravi P. Sahu, Sanjay Batra, Prabodh K. Kandala, Thomas L. Brown, Sanjay K. Srivastava